Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 735-741

  Loubani, Osama ^a   Hoskin, David W ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adhesion molecule; NK cell; Paclitaxel

Indexed keywords

ALPHA INTEGRIN; BETA7 INTEGRIN; CELL ADHESION MOLECULE; PACLITAXEL;

ARTICLE; CELL ACTIVITY; CELL ADHESION; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LEUKEMIA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION; DOWN-REGULATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PACLITAXEL;

EID: 17444410009     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI, The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Am Chem Soc 93: 2325-2327, 1971.
2. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, van Vreckem A, Sylvester R, Awada A, Wildiers J and Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724-733, 2000.
3. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V and Colombo N: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1158-1160, 2002.
4. Yasuda K, Igishi T, Kawasaki Y, Kato K, Matsumoto S, Katayama S, Sako T, Shigeoka Y, Suyama H, Sugitani A, Yamamoto M, Hitsuda Y and Shimizu E: Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 6: 347-352, 2004.
5. Amos LA and Lowe J: How taxol stabilises microtubule structure. Chem Biol 6: R65-69, 1999.
6. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178, 2000.
7. Horwitz SB: Taxol (paclitaxel): mechanisms of action. Ann Oncol Suppl 6: S3-6, 1994.
8. Park S-J, Wu C-H, Gordon JD, Zhong X, Emami A and Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279: 51057-51067, 2004.
9. Sangrajrang S and Fellous A: Taxol resistance. Chemotherapy 46: 327-334, 2000.
10. Chan OTM and Yang L-X: The immunological effects of taxanes. Cancer Immunol Immunother 49: 181-185, 2000.
11. Mullins DW, Burger CJ and Elgert KD: Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 162: 6811-6818, 1999.
12. Manthey CL, Perera PY, Salkowski CA and Vogel SN: Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 152: 825-831, 1994.
13. White CM, Martin BK, Lee LF, Haskill JS and Ting JP: Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 46: 104-112, 1998.
14. Mullins DW, Koci MD, Burger CJ and Elgert KD: Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol Immunotoxicol 20: 473-492, 1998.
15. Tange S, Scherer MN, Graeb C, Weiss T, Justl M, Frank E, Andrassy J, Jauch KW and Geissler EK: The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 73: 216-223, 2002.
16. Joo HG: Altered maturation of dentritic cells by taxol, an anticancer drug. J Vet Sci 4: 229-234, 2003.
17. Chuang LT, Lotzova E, Heath J, Cook KR, Munkarah A, Morris M and Wharton JT: Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res 54: 1286-1291, 1994.
18. Puente J, Diaz M, Salas MA, Miranda D, Gaggero A, Wolf ME and Mosnaim AD: Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. Int J Clin Pharmacol Ther 33: 457-461, 1995.
19. Tarazona R, Lopez-Lluch G, Galiani MD, Aguado E, Barahona F, Solana R and Pena J: HLA-B2702 (77-83/83-77) peptide binds to beta-tubulin on human NK cells and blocks their cytotoxic activity. J Immunol 265: 6776-6782, 2000.
20. Sako T, Burioka N, Yasuda K, Tomita K, Miyata M, Kurai J, Chikumi H, Watanabe M, Suyama H, Fukuoka Y, Ueda Y and Shimizu E: Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncol 43: 15-19, 2004.
21. Helander TS and Timonen T: Adhesion in NK cell function. Curr Top Microbiol Immunol 230: 89-99, 1998.
22. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M et al: TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134: 1623-1630, 1985.
23. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
24. Zhao C, Morgan M, Haeryfar SMM, Blay J and Hoskin DW: Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother 52: 185-193, 2003.
25. Bhan V, Mader JS and Hoskin DW: In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells. Oncol Rep 11: 893-897, 2004.
26. Perico N, Ostermann D, Bontempelli M, Morigi M, Amuchastegui CS, Zoja C, Akalin E, Sayegh MH and Remuzzi G: Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 7: 594-601, 1996.
27. Jordan A, Hadfield AJ, Lawrence NJ and McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18: 259-296, 1998.
28. Mehta S, Blackinton D, Manfredi M, Rajaratnam D, Kouttab N and Wanebo H: Taxol pretreatment of tumor targets amplifies natural killer cell mediated lysis. Leuk Lymphoma 26: 67-76, 1997.
29. Roth W, Wagenknecht B, Grimmel C, Dichgans J and Weller M: Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer 77: 404-411, 1998.
30. Glazyrin AL, Adsay VN, Vaitkevicius VK and Sarkar FH: CD95-related apoptotic machinery is functional in pancreatic cancer cells. Pancreas 22: 357-365, 2001.
31. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES and Perussia B: Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375-2380, 1998.
32. Biron CA: Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 9: 24-34, 1997.
33. Piccioli D, Sbrana S, Melandri E and Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195: 335-341, 2002.
34. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H and Smyth MJ: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3: 83-90, 2002.